Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists

Publisher： Bentham Science Publishers

E-ISSN： 1874-4702|11|2|113-121

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.11, Iss.2, 2018-04, pp. : 113-121

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypoxia Selects for a Quiescent, CML Stem/Leukemia Initiating- Like Population Dependent on CBP/Catenin Transcription

By  

Current Molecular Pharmacology, Vol. 6, Iss. 3, 2013-11 ,pp. : 204-210

Bentham Science Publishers

Access to resources Recommend Favorite

Nilotinib effective in imatinib-resistant/intolerant CML

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Dasatinib: a once-daily option for imatinib-resistant CML

By  

Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Dasatinib a START-R in imatinib-resistant CML

By  

Inpharma, Vol. 1, Iss. 1544, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Dasatinib off to a good start in imatinib-resistant CML

By  

Inpharma, Vol. 1, Iss. 1523, 2006-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite